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Table 1. Survival Outcomes of Second Transplants: Patient Characteristics
Patient characteristics All patients (%) Auto/Auto Auto/Allo Allo/Allo
All patients 52 (100%) 12 (23%) 31 (60%) 9 (19%)
Matched Related Donors(MRD) 17 (33%) 0 (0%) 13 (25%) 4 (8%)
Unrelated Donors(URD) 21 (39%) 0 (0%) 18 (35%) 3 (6%)
Autologous Donors 12 (23%) 12 (23%) 0 (0%) 0 (0%)
Syngeneic Donors(Syn) 2 (4%) 0 (0%) 0 (0%) 2 (4%)
Overall survival (1yr) 47% (95% CI 40%-54%) 64% 37% 56%
Overall survival (5yrs) 32% (95% CI 25%-39%) 18% 32% 44%
Relapse at 1 yr 17 (33%) 4 (7%) 12 (23%) 1 (2%) Syn
Treatment related mortality (TRM) at 1 yr 8 (15%) 0 (0%) 5 (10%) 3 (6%)
Cause of death at 1 yr 4 (8%)%MOF;1(2%) GVHD 2 (4%) GVHD;1(2%) PTLD
Acute GVHD(III-IV) 2 (4%) 0 (0%) 1 (2%) 1 (2%)
Chronic GVHD( flare) 18 (35%) 0 (0%) 13 (25%) 5 (10%)
Chronic GVHD(De novo) 2 (4%) 0 (0%) 2 (4%) 0 (0%)
Auto indicates Autologous; Allo, allogeneic; GVHD, graft versus host disease.
Poster Session II S341transplant. Median survival of patients who survived beyond first 30
days after second transplant was 352 days (36-5777 days). The cu-
mulative incidence of grade III-IV acute GVHD was 10 % (n 5 2).
The cumulative incidences of relapse at 1 and 5 years were 33% and
43%respectively. Probabilities of overall survival at 1 and5 yearswere
47% (95% CI 40-54%) and 32% (95% CI 25%-39%), respectively.
Disease recurrence was most frequent primary cause of death in 33%
(n5 18) pts at 1year. TRM was 7% at 30 days; 11% at 100 days and
15% at one year. The causes of TRM at one year included GVHD: 6
% (n5 3), multi organ failure: 7% (n5 4), PTLD 2% (n5 1).
Conclusion: Patients undergoing second transplants can achieve
long term survival beyond 5 years. Relapse, GVHD or early TRM
are still causes of morbidity after second transplant.
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RADIATION EXPOSURE FROM DIAGNOSTIC PROCEDURES IN ALLOGE-
NEIC STEM CELL TRANSPLANTATION DOES NOT SIGNIFICANTLY IMPACT
OVERALL SURVIVAL OR NON-RELAPSE MORTALITY
Battiwalla, M., Fakhrejahani, F., Klotz, J., Pophali, P., Draper, D.,
Haggerty, J., McIver, Z., Chawla, K., Ito, S., Barrett, J. NHLBI,
NIH, Bethesda, MD
Introduction:Diagnostic radiology procedures in the context of al-
logeneic stem cell transplantation (ASCT) impose an unknown risk
of radiation exposure. We conducted a retrospective study on radia-
tion exposure in the peri-transplant period to define this risk.
Methods: 64 consecutive patients underwent sibling ASCT after
conditioning with TBI 1200 cGy or 400 cGy, fludarabine 125 mg/
m2 and cyclophosphamide 120 mg/kg utilizing CD34+ selected
PBSC and cyclosporine as GVHD prophylaxis. 24 patients received
5x10 e6 CD3+/kg donor lymphocytes selectively depleted of allor-
eactivity by ex vivo photodepletion.
Diagnostic procedures (X-rays, CT Scans, fluoroscopy, and nu-
clear medicine (NM)) were documented for each individual in three
periods (day-30 to 0, day +1-100 and day +101-200). Radiation expo-
sure was calculated using the ‘‘effective dose’’ (ED) in mSv by mea-
surement or from literature review. Overall survival (OS) and
nonrelapse mortality (NRM) were evaluated in 55 subjects who sur-
vived.200 days in univariate analysis andmultivariable Coxmodels.
The variables for the cumulative and the periodic ED were forced
into the models.
Results: Patients underwent a median of 11 X-rays, 10 CT-scans,
0 nuclear medicine studies, and 1 fluoroscopic procedure. The me-
dian cumulative radiation exposure from diagnostic radiology proce-
dures was 91.6 mSv (range 1.2-300.1), equivalent to \10% of
a standard 1200 TBI dose. 29% of the cumulative ED was delivered
fromday -30 to 0, 65% fromday +1-100 and only 6% fromday +101-
200. The relative contributions from CT scans, X-rays, fluoroscopy,
and NM were 88%, 6%, 5% and\1%, respectively.
In univariate analysis, the cumulative dose of incidental radiation
from day -30 to +200 (p\0.03) and from day -30 to +100 (p\0.05)
were significantly associated with OS. The cumulative dose of inci-
dental radiation from day-30 to +100was also significantly associated
with NRM (p\0.03).In multivariable analysis, cumulative doses of radiation lost statis-
tical significance and were displaced by serum creatinine and serum
albumin in the final models for OS and by albumin, acute GVHD
and photodepletion for NRM.
Conclusions: Total radiation exposure from diagnostic radiation
was only a small fraction of radiation utilized in conditioning. CT
scans provided 90% of the radiation exposure. While the cumula-
tive dose of incidental radiation exposure was associated with OS and
NRM in univariate analysis, it was not significant in multivariable
analysis.
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HIGH RESOLUTION 9/10 OR 10/10 HLA MATCHED UNRELATED DONOR
STEM CELLS CONTRIBUTE A BETTER OUTCOME OF TRANSPLANT IN SE-
VERE THALASSEMIA PATIENTS
Hongeng, S., Pakakasama, S., Anurathapan, U., Sirachainan, N.,
Songdej, D., Chuansumrit, A. Ramathibodi Hospital, Mahidol University,
Bangkok, Thailand
We reviewed transplant outcome in 34 consecutive children and
adolescents with severe thalassemia who underwent allogeneic stem
cell transplantation with unrelated donors between September
1992 and July 2011.Thefirst cohort 22 patients underwent transplant
from 4/6, 5/6 or 6/6 allele HLA matched unrelated donors and the
second cohort 12 patients underwent transplant from 9/10 or 10/10
HLA matched unrelated donors. The myeloablative conditioning
regimen (MC) consisted of cyclophosphamide, busulfan (BU), flu-
darabine (FLU) and antithymocyte globulin (ATG) and nonmyeloa-
blative (NC) consisted of BU, FLU and ATG. The GVHD
prophylaxis for MC consisted of tacrolimus and MTX and for NC
consisted of tacrolimus andMMF.The purpose of NCwas for toxic-
ity reducing in the patients older than 10 years of age. Of 34 patients,
29 received bone marrow, 4 received peripheral blood and 1 received
cord blood stem cells. The 2-year thalassemia-free survival rate for
the first 22 cohort patients was 71% and 93% for the second cohort
12 patients (p 5 0.045). We suggest that high resolution 9/10 or
10/10 matched unrelated donor stem cells may significantly improve
the thalassemia free survival among severe thalassemia patients
who underwent unrelated donor transplantation.
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CLINICAL OUTCOMES AND COSTS OF SECOND ALLOGENEIC HEMATO-
POIETIC CELL TRANSPLANTATION
Khera, N.1, Storer, B.E.1, Chapko, M.K.2, Lee, S.J.1 1Fred Hutchinson
Cancer Research Center, Seattle, WA; 2VA Puget Sound, Seattle, WA
Background: In this era of growing health care costs, the decision to
proceed with a second allogeneic transplant has financial as well as
clinical implications.
Methods: We analyzed all medical costs for the transplant process
from the beginning of conditioning to 100 days after the transplant
for 55 patients who underwent second allogeneic transplants from
1/19/05 to 4/9/10 at the University of Washington/Seattle Cancer
